Oral Antibiotics Market Research, 2032
The global oral antibiotics market size was valued at $22.5 billion in 2022, and is projected to reach $28.8 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032. Oral antibiotics are medications that are ingested by the mouth and designed to treat bacterial infections. They are available in various forms such as tablets, capsules, or liquids. Once absorbed into the bloodstream through the digestive system, oral antibiotics target and kill bacteria or inhibit their growth.
Oral antibiotics are widely used to treat a range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and gastrointestinal infections. Oral antibiotics are prescribed based on the type of infection, the specific bacteria involved, and patient factors such as allergies and medical history.
Market Dynamics
The oral antibiotics market size is driven by several factors that contribute to its growth and development. The increase in the prevalence of infectious diseases and bacterial infections globally creates a high demand for oral antibiotics as an effective treatment option. In addition, the rise of antibiotic-resistant bacteria necessitates the development and use of new and improved oral antibiotics to combat these resistant strains.
Furthermore, the growth in the global population, coupled with improved access to healthcare services, increases the overall consumption of oral antibiotics. Moreover, the expanding geriatric population, who are more susceptible to infections, contributes to the demand for oral antibiotics and drives the oral antibiotics market growth.
In addition, advancements in healthcare infrastructure, particularly in developing economies, play a significant role in the market growth by improving access to oral antibiotics and increase in awareness about their benefits. In addition, continuous investments in R&D activities by pharmaceutical companies lead to the introduction of innovative oral antibiotics with enhanced efficacy and safety profiles.
However, Factors that restrain the growth during oral antibiotics market forecast include the rise of antibiotic resistance, stringent regulatory requirements, adverse effects and safety concerns associated with certain antibiotics, and the increasing preference for non-antibiotic alternatives. Moreover, the availability of over-the-counter medications and self-medication practices can hinder market growth by reducing the need for prescription antibiotics.
The demand for oral antibiotics does indeed tend to remain relatively stable during economic downturns due to their essential role in treating various health conditions. The necessity of antibiotics for combating infectious diseases ensures a consistent need for these drugs. Furthermore, the increasing aging population, often more susceptible to infections, contributes to sustained demand for therapeutic drugs like oral antibiotics.
However, Pharmaceutical companies may face challenges in research and development efforts due to funding constraints, potentially slowing down the introduction of new and innovative oral antibiotics to the market.
For instance, according to the report of Deloitee in January 2023, stated that the Projected return on investment in pharma R&D in 2022 has fallen to 1.2 per cent, the lowest ROI seen in the 13 years since the research began. In addition, with longer development cycle times, the average cost of developing a new drug rose by $298m to $2.3bn in 2022. Thus, these challenges can impact the industry's ability to address emerging antibiotic resistance and develop more effective treatments. Despite stable demand, the financial constraints within the pharmaceutical sector can impede progress in antibiotic research and development.
Segmental Overview
The oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides and others. Beta-lactam & beta-lactamase inhibitors are further segmented into penicillin, cephalosporin and others. On the basis of application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental and others. Community-respiratory tract infections (CARTIS) is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs).
On the basis of drug origin, the market is categorized into natural, semisynthetic and synthetic. On the basis of spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and mid/narrow-spectrum antibiotic. On the basis of drug type, the market is divided into branded and generics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
By Class
The Oral antibiotics market is segmented into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. The beta lactam & beta lactamase inhibitors segment held the highest market share in terms of revenue in 2022 and expected to maintain its dominance throughout the forecast period, owing to their broad-spectrum activity and effectiveness against a wide range of bacteria.
However, the emergence of bacterial resistance due to beta lactamase production poses a challenge. Beta lactamase inhibitors, such as clavulanic acid and sulbactam, are combined with beta lactam antibiotics to enhance their effectiveness to address this. However, the quinolone segment is expected to experience the highest compound annual growth rates (CAGRs) due to the increase in prevalence of resistant bacteria and their diverse range of applications in respiratory tract infections, urinary tract infections, gastrointestinal infections, and skin and soft tissue infections.
By Spectrum of Activity
The oral antibiotics market is divided into broad-spectrum antibiotic and Mid/Narrow-spectrum antibiotic. The broad-spectrum antibiotic segment held the highest market share in terms of revenue in 2022 and is expected to maintain its dominance throughout the forecast period, it is attributed to versatility, effectiveness, and strategic importance of broad-spectrum antibiotics in the treatment of various infections, especially in the face of increasing antibiotic resistance.
By Application
The oral antibiotics industry is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. The urinary acquired tract infections (UTIS) segment occupied highest share in 2022 and is expected to remain dominant during the forecast period, as it is the leading hospital-acquired infection, representing approximately 40% of all nosocomial infections. Females have a higher inclination to acquire UTIs compared to males.
Furthermore, the prevalence of diabetes plays a significant role in driving the growth of UTIs. Diabetic patients are more susceptible to UTIs due to immune system abnormalities associated with their condition. The combination of these factors contributes to the increased incidence of UTIs and underscores the need for effective prevention and treatment strategies in healthcare settings.
By Drug Origin
The oral antibiotics industry is classified into natural, semisynthetic, and synthetic on the basis of drug origin. The semisynthetic segment occupied highest share in 2022 and is expected to remain dominant during the forecast period, owing to the enhanced coverage and effectiveness of semisynthetic oral antibiotics against a diverse range of organisms.
On the other hand, the synthetic segment is expected to experience the highest compound annual growth rate (CAGR) in the oral antibiotic market due to the increase in demand for synthetic membrane-targeted antibiotics driven by antimicrobial resistance concerns. In addition, synthetic antibiotics offer several advantages over existing antibiotics, including a broad spectrum of activity, no cross-resistance with current antibiotics, rapid bactericidal activity, and a low likelihood of developing resistance.
By Drug Type
The oral antibiotics market is bifurcated into branded and generics on the basis of drug type. The branded segment occupied highest oral antibiotics market share in 2022 and is expected to remain dominant during the forecast period. Brand recognition, substantial research and development investments, robust patent protection, physician prescribing practices, and effective marketing strategies play a vital role in maintaining the market share and revenue of branded oral antibiotics.
However, the generic segment is expected to witness the highest compound annual growth rate (CAGR) in the oral antibiotic market. This is primarily due to the affordability of generic alternatives compared to branded medications. Furthermore, regulatory agencies in different countries have implemented pathways and regulations that promote the development and approval of generic drugs.
By Region
The Oral antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific accounted for the largest oral antibiotics market share in terms of revenue in 2022 and is expected to maintain its dominance during the forecast period. This growth can be attributed to several factors such as the significant consumption of antibiotics in the region, easy availability of antibiotics, and the rise in sales of antibiotics without prescription. The high prevalence of infectious diseases in the Asia-Pacific region also drives the demand for oral antibiotics. Furthermore, its large population base, diverse patient pool, and relatively lower costs of diagnosis and treatment compared to developed countries is further driving the market in this region.
Moreover, a rise in research activities as well as the well-established presence of domestic companies in the region are expected to provide notable opportunities for market growth. In addition, a rise in contract manufacturing organizations within the region provides is expected to open new avenues for market growth.
Competition Analysis
Competitive analysis and profiles of the major players in the Oral antibiotics market such as Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited. key players have adopted strategies such as product launch, acquisition and collaboration to enhance their product portfolio.
Recent Acquisition in the Oral Antibiotics Market
In October 2021, Sandoz, a Novartis division, announced successful completion of acquisition of cephalosporin antibiotics business of GSK. Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Recent Product Launch in the Oral Antibiotics Market
In May 2021, Teva Pharmaceutical Industries Ltd., a global leader in generic and specialty medicines, announced the launch of its 250mg and 500mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals. Teva generic erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.
Recent Collaboration in the Oral Antibiotics Market
In November 2021, F. Hoffmann-La Roche Ltd., announced that it has entered into a Research Collaboration and License Agreement with Venatorx Pharmaceuticals to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”) in gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE).
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antibiotics market analysis from 2022 to 2032 to identify the prevailing oral antibiotics market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the oral antibiotics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global oral antibiotics market trends, key players, market segments, application areas, and market growth strategies.
Oral Antibiotics Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 28.8 billion |
 Growth Rate | CAGR of 2.5% |
 Forecast period | 2022 - 2032 |
 Report Pages | 497 |
 By Application |
|
 By Class |
|
 By Spectrum of Activity |
|
 By Drug Origin |
|
 By Drug Type |
|
 By Region |
|
 Key Market Players | Cipla Ltd, Alkem Laboratories Ltd., Pfizer Inc., Lupin, Novartis AG, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Limited, Abbott Laboratories, SUN PHARMACEUTICAL INDUSTRIES LIMITED, Bayer AG |
Analyst Review
The oral antibiotic market presents several opportunities and challenges. The growth in prevalence of infectious diseases across the globe remains a key driver, thus, the demand for effective antibiotics continues to rise, providing opportunities for market expansion.
The expanding global population, particularly the aging demographics, contributes to the demand for effective drugs that are susceptible to infections increases. Moreover, a growth in initiative by pharma companies to enhance antibiotics R&D, and technological innovations in oral antibiotics significantly boost the growth of the oral antibiotics market. However, development of antibiotic resistance, driven by misuse of antibiotics, and increase in drug approval costs are expected to hinder the market growth. In addition, improved healthcare infrastructure, especially in developing regions, enhances access to diagnosis and treatment, contributing to the growth in demand for antibiotics.
Furthermore, in the North American region, several factors contribute to the growth of the oral antibiotics market. The increase in prevalence of bacterial infections and the rise in burden of antimicrobial resistance drive the demand for effective antibiotics in the market. In addition, Asia-Pacific is anticipated to witness notable growth during the forecast period owing to rise in antimicrobial resistance, which leads pharmaceutical companies toward R&D for next-generation antibiotics.
Oral antibiotics are medications that are administered by the mouth and designed to treat bacterial infections. They work by either killing the bacteria (bactericidal) or inhibiting their growth and reproduction (bacteriostatic).
The major factor that fuels the growth of the oral antibiotics market are rise in prevalence of infectious diseases ,increase in consumption of oral antibiotics and rise in investments in R&D activities drive the growth of the global oral antibiotics market .
The beta lactam & beta lactamase inhibitors segment is the most influencing segment in oral antibiotics market.This is attributed to its broad-spectrum activity and effectiveness against a wide range of bacteria.
Top companies such as Pfizer Inc, Abbott Laboratories, Novartis AG and Alkem Laboratories Ltd. held a high market position in 2022. These key players held a high market postion owing to the strong geographical foothold in North America, Europe, Asia-Pacific, and LAMEA.
The base year is 2022 in oral antibiotics market .
The market value of oral antibiotics market in 2032 is $28.8 billion
The forecast period for oral antibiotics market is 2023 to 2032
The total market value of oral antibiotics market is $22.4 billion in 2022.
Loading Table Of Content...
Loading Research Methodology...
